ArticleNature and science of sleep2025
Prevalence of Insomnia and Associated Factors in Female Patients Undergoing Chemotherapy.
Article in Nature and science of sleep, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Insomnia places significant physical and psychological burdens on female cancer patients undergoing chemotherapy, affecting their quality of life. This study aimed to investigate the prevalence of insomnia and its associated factors in female outpatients receiving chemotherapy. Patients and Methods: A cross-sectional study was conducted with female cancer patients receiving chemotherapy. The questionnaire included items assessing sociodemographic and clinical characteristics. Insomnia was measured using the Insomnia Severity Index. Results: A total of 206 female patients undergoing chemotherapy were included, with a mean age of 56.1 years (SD ± 11.7). The most common cancer types were breast (57.3%), gastrointestinal (22.8%), and gynecological malignancies (19.9%). Based on the Insomnia Severity Index (ISI), 34.0% of participants had subclinical insomnia and 17.0% had clinical insomnia. Increasing age was significantly associated with lower insomnia severity (aOR: 0.971; 95% CI: 0.945-0.998; p = 0.038). Among gynecological cancer patients, insomnia was more prevalent in those receiving treatment for metastatic disease (76.2% vs 35.0%). Psychiatric conditions (depression and/or anxiety) requiring medication and the presence of pain were both significantly associated with higher rates of insomnia (p < 0.001 for both). Conclusion: Insomnia was highly prevalent among female cancer patients undergoing chemotherapy. Younger age, presence of pain, psychiatric comorbidities (particularly depression and/or anxiety), and metastatic disease status emerged as significant correlates. Considering the relationship between insomnia and physical and psychological distress, it is anticipated that regular screening and treatment approaches for insomnia will contribute to the holistic cancer care process by improving patient quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.